Why Is Xeljanz XR So Hard to Find? [Explained for 2026]

Xeljanz XR (tofacitinib extended-release) is a once-daily oral JAK inhibitor made by Pfizer. It treats rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis — conditions that can seriously impact your quality of life. For patients who rely on it, not being able to fill a Xeljanz XR prescription is more than an inconvenience. It can mean returning pain, stiffness, and flares.

So why is Xeljanz XR hard to find? The answer isn't a traditional drug shortage. Instead, it's a combination of insurance hurdles, specialty pharmacy restrictions, and high costs that create real barriers between patients and their medication.

Is There a Xeljanz XR Drug Shortage in 2026?

As of 2026, Xeljanz XR is not listed on the FDA's official drug shortage database. Unlike some medications — such as certain generic ADHD drugs or GLP-1 injectables — Xeljanz XR is manufactured in adequate quantities. Pfizer has continued producing this medication consistently since its approval.

However, "no official shortage" does not mean "easy to find at your local pharmacy." Xeljanz XR is a specialty medication, which creates its own set of access barriers that feel very much like a shortage to patients trying to fill it.

Why Does Xeljanz XR Require Prior Authorization?

Prior authorization (PA) is the number one reason patients have difficulty filling Xeljanz XR. Nearly every major insurance plan — including commercial plans and Medicare Part D — requires PA before they'll cover this medication. This means your doctor must submit documentation proving you meet the plan's criteria.

For Xeljanz XR, this typically means:

You must have a confirmed diagnosis of RA, PsA, AS, or UC

You must have tried and failed at least one TNF blocker (e.g., adalimumab, etanercept) in many plans

Your prescriber must be a specialist (rheumatologist or gastroenterologist) in some cases

The PA may require lab results, medical records, and documentation of previous treatments

This process can take days to weeks. During that window, you may be unable to fill your prescription even though pharmacies have the medication in stock.

What Is Step Therapy and How Does It Affect Xeljanz XR Access?

Step therapy — sometimes called "fail first" — is an insurance policy that requires you to try and fail less expensive treatments before the plan will cover a more costly option like Xeljanz XR. This is extremely common for JAK inhibitors.

In practice, this often means patients must first try a conventional DMARD (like methotrexate) and then a TNF blocker biologic (like Humira or Enbrel) before their insurer will approve Xeljanz XR. For patients who have already been on those medications — or who have medical reasons to avoid them — this requirement can lead to delays of months.

Why Is Xeljanz XR Only at Specialty Pharmacies?

Xeljanz XR is classified as a specialty drug, which means many insurance plans require it to be dispensed through a specialty pharmacy rather than your neighborhood drugstore. Specialty pharmacies include services like CVS Specialty, Walgreens Specialty, Optum Specialty, and AccordantCare.

This restriction exists because specialty medications typically require specialized handling, patient education, and closer monitoring. While this is meant to protect patients, it also creates friction: patients may be surprised to learn their local pharmacy can't fill the prescription, and the specialty pharmacy may require additional paperwork or insurance verification before dispensing.

How Does the Cost of Xeljanz XR Create Access Barriers?

The retail cash price of Xeljanz XR is approximately $8,700 per month for a 30-day supply of the 11 mg tablet. This places it firmly in the category of specialty medications that are out of reach for most patients without insurance coverage or manufacturer assistance.

Even with insurance, patients may face high specialty copays, step therapy requirements, or coverage denials that leave them temporarily unable to access the medication. If your insurance changes — new employer, new plan year, or a switch to Medicare — you may face a coverage gap while the new plan's PA process plays out.

What About Generic Tofacitinib — Is It Easier to Find?

Generic tofacitinib in the immediate-release form (equivalent to Xeljanz 5 mg tablets) has been available since June 2021. The FDA also approved a generic version of Xeljanz XR (extended-release) from Ajanta Pharma in August 2025, though retail availability remains limited.

If your plan covers generic tofacitinib, you may find it significantly cheaper and easier to obtain. Talk to your prescriber about whether switching from Xeljanz XR to generic tofacitinib IR tablets (5 mg twice daily instead of 11 mg once daily) is an option for you, as both deliver the same active ingredient.

Tips for Patients Who Can't Fill Their Xeljanz XR Prescription

Here's what to do if you're struggling to access Xeljanz XR:

Contact your prescriber's office about your PA status and any appeals if denied.

Ask about the Pfizer XELJANZ Co-Pay Savings Program (1-844-935-5269) if you have commercial insurance.

Inquire about Pfizer RxPathways for patient assistance if you are uninsured or underinsured.

Ask your doctor if generic tofacitinib IR is a suitable alternative for your condition.

Use medfinder to find out which pharmacies near you carry Xeljanz XR and can fill your prescription.

The Bottom Line

Xeljanz XR is not in a clinical drug shortage, but access barriers — prior auth, step therapy, specialty pharmacy restrictions, and cost — make it genuinely difficult for many patients to fill. Understanding these barriers is the first step to working around them. For step-by-step guidance on locating Xeljanz XR near you, read our guide on how to find Xeljanz XR in stock near you.

If cost is the barrier, our guide to saving money on Xeljanz XR covers coupons, copay cards, and patient assistance programs in detail.